anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Orbital apex syndrome (OAS) is a condition characterised by lesions within the orbital apex, leading to various ophthalmologic symptoms. This study aimed to analyse the clinical characteristics and treatment strategies of OAS with respect to aetiology.
METHODS: This retrospective analysis utilised data from 5 medical institutions between 2013 and 2022. Patients who were diagnosed with OAS were initially enrolled, but patients who failed to follow up at least 1 month were excluded. The prevalence of initial ophthalmologic symptoms and visual improvement after treatment was compared according to aetiology. Factors related to visual improvement were analysed.
RESULTS: Among 73 enrolled patients, the leading aetiology was tumours, followed by fungal infections and inflammation. Visual impairment and proptosis were prevalent in tumour-related OAS cases. Inflammation-related OAS exhibited a higher likelihood of painful eye movements and ophthalmoplegia. Ptosis was most frequently observed in fungal infection-related OAS. Notably, fungal infections emerged as the sole significant factor negatively impacting vision progression. In inflammation-related OAS, the time interval between symptom onset and the administration of steroids was longer in patients without visual improvement, even though there was no statistically significant difference.
CONCLUSIONS: Tumours were the predominant cause of OAS. Visual impairment was a common manifestation in tumour-related OAS, while fungal infections were strongly associated with a poor visual prognosis. The timely administration of steroids might be helpful for improving vision in patients with inflammation-related OAS. However, further studies are needed to enhance understanding and management of OAS.
Intraneural Facilitation Therapy is a novel manual therapy technique that seeks to enhance endoneurial capillary circulation, bias blood flow into the neural fascicle, and reverse intrafascicular ischemia. To redirect blood to the ischemic nerves, this passive approach involves tractioning skin, distending visceral tissues, stretching muscles, mobilizing joints, and stretching blood vessels. The Nerve Flossing Technique is an emerging treatment approach that aims to improve neurodynamic, range of motion, and quality of life. Intraneural Facilitation and Nerve Flossing Techniques address diabetic peripheral neuropathy, and their effectiveness in improving pain, balance, gait, and quality of life remains un-compared.

This randomized clinical trial will be conducted at Social Security Hospital, and Siddique Family Hospital, Gujranwala. 44 Participants who meet the inclusion criteria will be selected through a non-probability convenience sampling technique and randomly allocated into two groups using an online randomizer tool. Participants will be included in Groups A (Intraneural Facilitation Therapy) and Group B (Nerve Flossing Technique). A total of 24 sessions (3x/week for 8 weeks) will be conducted, lasting 60 minutes each.. A Numeric Pain Rating scale will be used to assess pain, the Berg Balance Scale (BBS) to assess balance, a 4-item Dynamic Gait Index to assess Gait, and the Quality of Life-Diabetic Neuropathy (QOL-DN) for quality of life. Assessment will be carried out at baseline (before treatment), after the 8th week (post-intervention), and at a 2-month follow-up. The data will be entered and analyzed using the IBM SPSS Statistics 27.0 version. Statistical significance will be set at p ≤0.05.
The present invention provides: a novel disubstituted 1, 2, 4-triazine compound that has an aldosterone synthase inhibitory activity and is useful in the prevention and/or treatment of various diseases or symptoms involving aldosterone, or a pharmaceutically acceptable salt of said compound; a method for producing same; a use for same; and a pharmaceutical composition, etc. formed using the compound or pharmaceutically acceptable salt thereof as an active ingredient. Provided is a compound represented by general formula [I]: [In the formula, RA is a group, etc. represented by formula (A-1) (in the formula, ring A1 is an optionally substituted cycloalkyl group, etc.), and RB is a monocyclic cycloalkyl group, etc.], or a pharmaceutically acceptable salt of said compound.
Open reduction and internal fixation with 1/3 semitubular plate and screws. Post-operatively, surgically treated ankles are placed in a below-the-knee cast for six weeks. They are advised to carry out partial weight-bearing (15 to 20 kilograms) for the first four weeks and then weight-bear as tolerated for the remaining two weeks.
The brief motivational interview (BMI) to be tested in the RCT in Pretoria is a one-session, 45 minute intervention that will coordinate three, 15-minute modules with one module each to (1) reduce hazardous drinking; (2) reduce illicit drug use; and (3) promote condom use. Each module is delivered by the clinician using a two-sided laminated card that includes scripted questions and visual aids. Consistent with brief intervention models, the BMI intervention is delivered during one 45 minute session with advice giving as a primary characteristic. Motivational interviewing is also incorporated within the BMI intervention by using a client-centered method of communication to foster behavior change through five techniques of expressing empathy, developing discrepancy, avoiding argumentation, supporting self-efficacy, and motivational rules.
Research and development in genetic testing for cancer susceptibility genes has advanced rapidly in recent years, allowing healthy individuals, cancer patients, and their families to determine if they carry mutations which increase their risk of breast, ovarian, prostate, colon, and other cancers. Initial efforts have unfolded primarily in academic medical centers targeting families at high risk for cancer. There is currently no information available for assessing the prevalence of genetic testing for cancer susceptibility genes at the national level, or for evaluating the knowledge of and attitudes toward such testing among primary care physicians. The objectives of this survey are to determine the utilization of genetic tests by physicians at the national level; to ascertain physician knowledge of available genetic tests for specific cancer susceptibility genes, to examine physicians' general attitudes toward testing, and; to explore possible variation in utilization and knowledge/attitudes by medical specialty, type of practice, year of training completion, board status, urbanicity, and geographic region. The primary research question that this survey will address is what is the prevalence of use of genetic testing for cancer susceptibility among primary care physicians in the U.S.? The survey will also assess whether there are statistically significant differences in 1) self-reported knowledge, current use of, and future intentions to use genetic testing for cancer susceptibility, and 2) perceptions of barriers to testing, among primary care physicians by their type and location of practice, and recency of training. Primary care physicians (general internists, obstetrician/gynecologist, family and general practitioners) will also be compared with specialty groups (gastroenterologists, surgeons, urologists) and oncologists with respect to their use, attitudes towards, and knowledge of, genetic testing for cancer susceptibility. A questionnaire was administered by mail, telephone, facsimilie or Internet to a nationally representative sample of 1,251 primary care physicians and specialists. Study participants are primary care and specialty physicians with active licenses to practice medicine in the U.S. A data file with personal identifiers deleted will be prepared for statistical analysis to estimate the prevalence and determine predictors of use and intentions to genetic tests for inherited cancer susceptibility.
The present invention discloses a health-care medicinal liquor for treating the protrusion of a lumbar intervertebral disc and a preparation method thereof. The effective ingredients of the medicinal liquor are prepared by the following raw materials in part by weight: 10-30 parts of white achyranthes, 10-25 parts of camphorwood, 8-26 parts of helwingia himalaica, 6-22 parts of radix paeoniae rubra, 10-28 parts of cattail pollen, 12-30 parts of Zanthoxylum nitidum, 5-25 parts of rattlesnake plantain, 5-15 parts of pumex, 5-15 parts of physalis angulata, 4-16 parts of walnut flowers, 5-15 parts of turtle shells, 5-20 parts of eucheuma gelatinae, 6-16 parts of fructus livistonae, 10-25 parts of munronia henryi harms, 5-20 parts of adiantum, 6-20 parts of primula forrestii, 10-20 parts of small diuranthera roots, 6-20 parts of lycopodium clavatum, 5-15 parts of blumea balsamifera, 6-20 parts of anisetree barks, 4-16 parts of cortex illicii, 6-20 parts of honghuoma, 10-20 parts of eucommia and 5-18 parts of Himalayan teasel root. According to the technical scheme of the invention, under the guidance of the traditional Chinese medicine theory and the clinical experience, the formula of above traditional Chinese medicines is elaborately selected. Therefore, the health-care medicinal liquor, prepared through the optimized preparation method, has the efficacies of promoting blood circulation to remove blood stasis, softening hardness, dissipating binds, relaxing muscles and tendons, stimulating the circulation of the blood, clearing heat, and dehumidifying. The medicinal materials of the above medicinal liquor are appropriate in compatibility, free of side effects, high in effective rate and difficult to recur. Meanwhile, both the internal application and the external application of the medicinal liquor are enabled. That means, the oral administration and the external inunction of the medicinal liquor are integrated.
Children will receive antiretroviral treatment (ART) until 6 weeks old after birth. For the first two weeks, Zidovudine (AZT), Lamivudine (3TC) and Nevirapine (NVP) will be used. When the child is 2 weeks old, the regimen will be adjusted and Nevirapine (NVP) will be replaced by Lopinavir/ritonavir (LPV/r). Early infant diagnosis and other relevant testing will be performed to monitor children's HIV infection status. If the child is not infected, ART will be stopped when he/she reaches 6 weeks old. Otherwise, the treatment will be continued.
PURPOSE: To establish the extent to which person-centered processes are integrated in assessment procedures, the Relationship, Assessment, Inclusion, Support, Evolve (R.A.I.S.E.) Assessment framework was used to evaluate measures that are typically used when assessing people living with primary progressive aphasia (PPA).
METHOD: Forty-five assessment tools were evaluated through the lens of the five R.A.I.S.E. principles: building the client-clinician Relationship, Assessment choices, Including the client and care partners, providing Support, and Evolving procedures to match client capability and progression. The principles were operationalized as questions for raters to evaluate whether a measure met this aspect of the R.A.I.S.E. Assessment framework.
RESULTS: Ten measures commonly used in the assessment of people living with PPA met all R.A.I.S.E. principles. These measures centered upon the elicitation of naturalistic discourse, conversation, client self-report, and clinician ratings. Thirteen measures did not meet any of the criteria, and represented standardized evaluation procedures do not provide the opportunity to connect to the client, elicit or provide feedback or support, nor to adapt in response to need or performance.
CONCLUSIONS: Whether using standardized or informal assessment tools, a relational and qualitative approach to providing assessment is paramount to promote client success and therapeutic engagement. We provide guidance through the R.A.I.S.E. framework on practices to cultivate person-centered processes of assessment in the care of people living with PPA.
The doctor leaves the antibiotic prescription, for the respiratory infection of the patient, at the reception of the primary care center 3 days after the first medical visit. This prescription can be collected by patient if he needed, in case of worsening of symptoms or not improving.
All patients underwent conventional CABG. After the main stage of the surgery 0.9% normal saline (1 mL at each fat pad; placebo group) was injected into the entire four visible area of the major epicardial fat pads. First epicardial left atrial fat pad is located anterior to the right superior pulmonary vein and corresponding to the anterior right GP; second epicardial fat pad is located inferoposterior to the right inferior pulmonary vein and corresponding to the inferior right GP; third fat pad is located anterior to the left superior PV and left inferior PV (between the PVs and LAA), corresponding to the Marshall tract GP and superior left GP; forth fat pad located inferiorly to the left inferior PV and extends posteriorly and corresponding to the inferior left GP.
Out of the 976 patients included in the ISPOCD2 study (Abildstrom H, Christiansen M et al. Apolipoprotein E genotype and cognitive dysfunction after noncardiac surgery. Anesthesiology 2004;101:855-61) the 93 patients with POCD whose blood samples are stored will be included together with 2x93 controls (without POCD), who will be matched by type of surgery, age, education, ASA-score and sex.
In phase II, a total of 300 eligible subjects will be randomly allocated in a 1:1 ratio to receive PIKA COVID-19 vaccine or the comparator inactivated COVID-19 vaccine. The ratio of the GMT of neutralizing antibody on Day 14 after the booster dose of PIKA COVID-19 vaccine group and inactivated COVID-19 vaccine group will be calculated. Based on the Phase I immunogenicity data of PIKA vaccine, the proposed Phase II sample size results in nearly 100% power in a two-sample t test of the log- transformed neutralizing antibody titers with a two-sided alpha=0.05. Among 300 subjects, at least 200 subjects will be enrolled as subset of long term immunogenicity and 100 subjects will be enrolled as subset of early immunogenicity. Among the 100 early immunogenicity subset, the ratio of the GMT of neutralizing antibody on Day 7 after the booster dose of PIKA COVID-19 vaccine group and inactivated COVID-19 vaccine group will be calculated. Therefore, the 100 subjects randomized to the early immunogenicity subset will have additional blood sampling on Day 7. After completion of the 7-day safety observation following the immunization of all subjects in the Phase II trial, a Safety Monitoring Committee (SMC) meeting will be held to determine whether to initiate enrollment of participants in the Phase III trial. In phase III, total 9,000 eligible subjects will be randomly allocated in a 1:1 ratio to the PIKA COVID-19 vaccine group or the comparator inactivated COVID-19 vaccine group. The sample size provides an approximately 90% power to detect a protection rate of at least 65% by PIKA vaccine in a Poisson regression analysis with a one-sided alpha of 0.025. The calculations consider an interim analysis performed with 50% of the information collected using a Pocock boundary to adjust for multiplicity. A 1% infection rate in the control group and an approximately a 10% attrition rate are assumed. It is of note that while the actual background incidence rate can vary, the sample size requirement amounts to achieving an observation of 82 COVID-19 cases to ensure the statistical power under the 65% protection rate assumption. Similarly, the interim analysis will need to be conducted at when approximately 41 cases are observed to maintain the planned operating characteristics. Among total subjects, at least 6% subjects will be enrolled as subset of immunogenicity. Eligible subjects will receive a dose of investigational vaccine via intramuscular injection in deltoid muscle on Day 0. All subjects will be monitored for at least 30 minutes after injection. Solicited AEs will be recorded for 7 days. Unsolicited AEs and MAAEs will be recorded for 28 days following injection. SAEs, SUSARs, AESIs will be recorded for the entire duration of the study. It will take about 13 months for each subject from enrollment to the last visit. Some subjects may withdraw or discontinue from the study during the study for any reason.
BACKGROUND: Ileostomy is the mainstay treatment option for various gastrointestinal conditions. Given the increased risk of post-discharge complications and high readmission rates that can be further aggravated by receiving care at different facilities (care fragmentation), further examination is necessary. We thus used a national cohort to explore the associations of care fragmentation among ileostomy patients experiencing adverse outcomes and increased hospitalization expenditures.
METHODS: All adult hospitalizations for ileostomy were tabulated from the 2016 to 2020 Nationwide Readmissions Database. Those readmitted within 90 days after discharge were included for analysis. Patients treated at a different facility than the original location where the index ileostomy was performed were categorized into the care-fragmented cohort. Multivariable regressions were developed to characterize the association of the care-fragmented cohort with postoperative outcomes, readmissions, and expenditures.
RESULTS: Of 52,254 patients with ileostomy creation hospitalizations with 90-day nonelective readmission, 9,045 (17.3%) experienced care fragmentation. Following risk adjustment, those experiencing care fragmentation faced increased odds of mortality (adjusted odds ratio 1.81, 95% confidence interval 1.54-2.12), cardiac (adjusted odds ratio 1.63, 95% confidence interval 1.42-1.85), respiratory (adjusted odds ratio 1.71, 95% confidence interval 1.53-1.91), infectious (adjusted odds ratio 1.33, 95% confidence interval 1.23-1.43), and thromboembolic (adjusted odds ratio 1.28, 95% confidence interval 1.13-1.45) complications. Furthermore, patients experiencing care fragmentation were more likely to have increased hospitalization costs ($1,700, 95% confidence interval 0.8-2.5).
CONCLUSION: Care fragmentation in ileostomy patients demonstrated an increased risk for mortality, postoperative complications, and increased hospitalization expenses. To mitigate risks for adverse outcomes, future studies should evaluate the impacts of inter-hospital communication with the goal of improving care continuity and optimizing healthcare delivery for care-fragmented populations.
The active ingredient in lansoprazole delayed-release capsules USP is lansoprazole, a substituted benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl] benzimidazole, a compound that inhibits gastric acid secretion. Lansoprazole has the following structure:

C16H14F3N3O2S M.W. 369.36

Lansoprazole is a white to brownish-white odorless crystalline powder which melts with decomposition at approximately 166°C. Lansoprazole is freely soluble in dimethylformamide; soluble in methanol; sparingly soluble in ethanol; slightly soluble in ethyl acetate, dichloromethane and acetonitrile; very slightly soluble in ether; and practically insoluble in hexane and water.

Lansoprazole is stable when exposed to light for up to two months. The rate of degradation of the compound in aqueous solution increases with decreasing pH. The degradation half-life of the drug substance in aqueous solution at 25°C is approximately 0.5 hour at pH 5.0 and approximately 18 hours at pH 7.0.

The lansoprazole delayed-release capsules USP for oral administration are available in two dosage strengths: 15 mg and 30 mg of lansoprazole per capsule. Each delayed-release capsule contains enteric-coated granules consisting of 15 mg or 30 mg of lansoprazole (active ingredient) and the following inactive ingredients: black iron oxide, gelatin, hypromellose, magnesium carbonate, methacrylic acid copolymer dispersion, propylene glycol, red iron oxide, shellac, sugar spheres (which contain sucrose and corn starch), talc, titanium dioxide, and triethyl citrate. Additionally, 15 mg capsule contains brilliant blue FCF - FD&C blue 1. The imprinting ink may contain potassium hydroxide.
This is a double-blind (neither the researchers nor the participants know what treatment the participant is receiving), placebo-controlled (an inactive substance; a pretend treatment \[with no drug in it\] that is compared in a clinical trial with a drug to test if the drug has a real effect), randomized (study drug assigned by chance), multi-center (when more than one hospital or medical school team work on a medical research study), parallel-group study. The study consists of 3 Parts; Screening Phase of 90 days, double-blind Treatment Phase of 6 months and Follow-up Phase of 7 to 28 days following the last dose in Month 6. Eligible participants in the early (predementia) AD spectrum will be randomized to either Treatment group 1, 2 or placebo and participants who previously participated in study 54861911ALZ1005 will be enrolled in this study and will receive the same treatment as in study 54861911ALZ1005. The study duration for each participant will be approximately 10 months. Blood and cerebrospinal fluid (CSF) samples will be collected to evaluate the plasma pharmacokinetics of JNJ-54861911, as well as amyloid beta fragments. Participants' safety will be monitored throughout the study, including magnetic resonance imaging (MRI) and cognitive measures.
Chidamide is a novel and orally active benzamide class of HDAC inhibitor that selectively inhibits activity of HDAC1, 2, 3 and 10, which can Induce tumor-cell apoptosis, suppress cell proliferation and enhance immune surveillance. Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1(DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function. Immune checkpoint inhibitors have emerged as effective therapies for many cancers by promoting the reactivation and restoring function of T cells.